Viatris logo

ViatrisNASDAQ: VTRS

Profile

Sector:

Healthcare

Country:

United States

IPO:

17 March 1980

Next earnings report:

07 November 2024

Last dividends:

23 August 2024

Next dividends:

N/A
$13.82 B
-25%vs. 3y high
94%vs. sector
-vs. 3y high
-vs. sector
-21%vs. 3y high
34%vs. sector
-12%vs. 3y high
22%vs. sector

Price

regular market | 3 min ago
$11.58-$0.12(-1.03%)
$3.80 B$3.71 B
$3.80 B-$326.40 M

Analysts recommendations

Institutional Ownership

VTRS Latest News

Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics
zacks.com04 November 2024 Sentiment: -

Besides Wall Street's top -and-bottom-line estimates for Viatris (VTRS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference
prnewswire.com29 October 2024 Sentiment: POSITIVE

PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a worldwide healthcare firm, has announced its participation in two upcoming healthcare conferences. More information about the presentations is provided below: UBS Global Healthcare Conference Date: Tuesday, November 12, 2024 Time: 8:45 a.m.

Viatris Named to Forbes' World's Top Companies for Women 2024 List
prnewswire.com29 October 2024 Sentiment: POSITIVE

PITTSBURGH, Oct. 29, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a worldwide healthcare firm, has been recognized on Forbes' 2024 list of the World's Top Companies for Women. This honor is given in partnership with Statista, a leading provider of statistics and industry rankings.

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe
globenewswire.com16 October 2024 Sentiment: POSITIVE

Lexicon will get an initial payment of $25 million, along with the possibility of additional payments based on regulatory and commercial achievements.

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe
prnewswire.com16 October 2024 Sentiment: POSITIVE

Viatris Inc. is expanding its innovative range of treatments for cardiovascular diseases by partnering with Lexicon Pharmaceuticals for the exclusive rights to sotagliflozin in markets outside the U.S. and Europe. This medication was approved by the U.S. FDA in May 2023 to help lower the risk of cardiovascular death and hospital visits related to heart failure in adults with certain health conditions. The agreement allows Viatris to utilize its global resources and expertise to explore more uses for sotagliflozin.

Viatris Announces the Pricing Terms of Maximum Tender Offer
prnewswire.com18 September 2024 Sentiment: POSITIVE

PITTSBURGH, Sept. 18, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has announced the pricing details for its cash tender offer, known as the "Maximum Tender Offer," made by its subsidiary Utah Acquisition Sub Inc. This offer is for up to a total of $575,003,000 of its outstanding 3.950% Senior Notes due in 2026, which must be validly submitted and not withdrawn by the Early Tender Date.

Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
prnewswire.com16 September 2024 Sentiment: NEUTRAL

PITTSBURGH, Sept. 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) is set to announce its financial results for the third quarter of 2024 on Thursday, November 7, 2024, before the U.S. markets open.

Viatris Announces Expiration and Results of Any and All Cash Tender Offers
prnewswire.com10 September 2024 Sentiment: POSITIVE

PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has announced that it, along with its subsidiary Mylan Inc., is proceeding with cash tender offers for all outstanding 1.650% Senior Notes due 2025 issued by Viatris. These offers are referred to as the "Any and All Tender Offers."

Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers
prnewswire.com10 September 2024 Sentiment: POSITIVE

PITTSBURGH, Sept. 10, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has announced the pricing details for its cash tender offers, which include both Viatris and its subsidiary Mylan Inc. These offers are for all outstanding 1.650% Senior Notes due 2025 from Viatris and 2.125% Senior Notes due 2025 from Mylan.

Viatris Announces Cash Tender Offers for Certain Outstanding Notes
prnewswire.com04 September 2024 Sentiment: POSITIVE

On September 4, 2024, Viatris Inc. announced that it and its subsidiaries, Mylan Inc. and Utah Acquisition Sub Inc., have started cash tender offers to buy back certain senior notes. These include all outstanding 1.650% Senior Notes due 2025 from Viatris, all 2.125% Senior Notes due 2025 from Mylan, and up to $450 million of 3.950% Senior Notes due 2026 from Utah Acquisition. The offers are aimed at purchasing these securities collectively referred to as the "Securities."

What type of business is Viatris?

Viatris Inc. is an American global pharmaceutical company formed as a result of the merger of Mylan and Upjohn on November 16, 2020. The company's headquarters is located in Canonsburg, Pennsylvania. The company manufactures and sells various types of medications: brand names (such as Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, over-the-counter drugs, and active pharmaceutical ingredients. They cover a wide range of therapeutic areas such as cardiovascular, infectious diseases, oncology, immunology, CNS and anesthesia, women's health, diabetes and metabolism, gastroenterology, respiratory and allergy, dermatology.

What sector is Viatris in?

Viatris is in the Healthcare sector

What industry is Viatris in?

Viatris is in the Drug Manufacturers - Specialty & Generic industry

What country is Viatris from?

Viatris is headquartered in United States

When did Viatris go public?

Viatris initial public offering (IPO) was on 17 March 1980

What is Viatris website?

https://www.viatris.com

Is Viatris in the S&P 500?

Yes, Viatris is included in the S&P 500 index

Is Viatris in the NASDAQ 100?

No, Viatris is not included in the NASDAQ 100 index

Is Viatris in the Dow Jones?

No, Viatris is not included in the Dow Jones index

When was Viatris the previous earnings report?

No data

When does Viatris earnings report?

The next expected earnings date for Viatris is 07 November 2024